Illumina (NASDAQ:ILMN) Announces Quarterly Earnings Results

Illumina (NASDAQ:ILMN) issued its quarterly earnings data on Thursday. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06), Zacks reports. Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%.

Illumina Trading Down 9.6 %

Shares of Illumina stock opened at $111.06 on Friday. The company has a 50-day moving average of $136.70 and a two-hundred day moving average of $135.29. Illumina has a 12-month low of $100.08 and a 12-month high of $156.66. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The stock has a market cap of $17.61 billion, a PE ratio of -14.46 and a beta of 1.10.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ILMN shares. Royal Bank of Canada decreased their target price on Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research report on Friday. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and decreased their price objective for the company from $177.00 to $140.00 in a report on Friday. Canaccord Genuity Group cut their target price on shares of Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a report on Friday. Stephens upped their price target on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Finally, Robert W. Baird raised their price objective on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Nine investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $161.40.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.